Global Dyslexia Treatment and Diagnosis Market to Grow at a CAGR of 7.30% During 2024–2032

Introduction

Dyslexia is a condition when the patient struggles with writing, reading, and remembering unfamiliar or complicated words. Dyslexia is a neurological learning problem present in a variety of populations. Utilizing specialist educational techniques, early dyslexia management in children is achievable. In addition, several online programs and resources help improve the reading and learning difficulties associated with dyslexia disease. The fundamental brain differences that cause dyslexia are now untreatable. However, success can be boosted with early detection, evaluation, and selection of the most appropriate therapy.

Market Dynamics

Increasing Prevalence of Dyslexia Drives the Global Market

According to global research, one in ten people have dyslexia. Additionally, according to a whitepaper titled "The Economic Impact of Dyslexia on California" issued by Boston Consulting Group (US) in July 2020, California would incur costs of roughly USD 12 billion in 2020 and USD 1 trillion over the following 60 years due to dyslexia. In a research paper published online in 2021 in the Indian Journal of Psychiatric Nursing, the rate of dyslexia in Indian primary pupils was reported to be between 2 and 18 percent. It is estimated that around 90 million Indians suffer learning difficulties of different severity. Thus, a vast population with learning difficulties susceptible to developing dyslexia is increasing the number of dyslexic patients. In addition, a rising number of dyslexia-specific learning programs contributes to expanding the worldwide dyslexia treatment and diagnostic market.

Rising Collaborations with Schools, Colleges, and Non-Profit Organizations Creates Tremendous Opportunities

Many schools specialize in educating students with learning disabilities. Similarly, non-profits support educational and financial resources for individuals with exceptional needs. For instance, the Baily Thomas Charitable Fund provides funds to registered organizations serving children or people with severe learning disabilities and Autism. Similarly, "Follow your Dreams" assists youth with learning disabilities reach their full potential. In contrast, the Forbes Charitable Foundation helps small and medium-sized organizations with capital expenditures and a portion of revenue expenditures through grants. App developers may partner with the government, curriculum designers, schools, and higher education institutions to deliver services and create income. Similarly, app developers may extend their business by attracting investment and startup capital from charity trusts, creating opportunities for market growth.

Regional Analysis

North America is the most significant contributor to the global dyslexia treatment and diagnosis market and is anticipated to grow at a CAGR of 6.15% during the forecast period. The region's market is driven by a developed healthcare infrastructure, favorable government legislation, substantial regional corporate headquarters, like Jubilant Cadista (U.S.) and Speechify (U.S.), and a high prevalence of dyslexia. According to the Dyslexia Center of Utah, one in five students, or 15% to 20% of the U.S. population, has a learning-based disorder. In addition, the region is home to various non-profit organizations with a global reach. These organizations aid people with dyslexia and their families and improve public awareness of the condition. Several prestigious schools in the region cater to dyslexic children. There are around 100 private schools for individuals with dyslexia in the United States and approximately six in Canada. The education ministry is likewise implementing market-growth-driving policies.

Europe is estimated to grow at a CAGR of 7.02% over the forecast period. Similar to North America, dyslexia is prevalent throughout Europe. According to a December 2019 Institute of Entrepreneurship Development (iED) survey, 15% of Europeans have dyslexia. In addition, a substantial proportion of the 15% of individuals with dyslexia also has additional co-morbid problems. Twenty to forty percent of persons with dyslexia also have dyscalculia, and ten to twenty percent have anxiety disorders. As a result, the region's requirement for high-quality medical treatment and diagnostic instruments is outstanding.

Furthermore, significant businesses with regional headquarters are innovating and pushing regional market expansion. For instance, the I.T. Accessibility Project at GlaxoSmithKline plc (U.K.) focuses on offering I.T. solutions to users and clients with impairments such as dyslexia. Additionally, the business declared in June 2021 that it would significantly increase its line of specialized pharmaceuticals over the forecast period.

Key Highlights

• The global dyslexia treatment and diagnosis market size was valued at USD 28.43 billion in 2023. It is expected to reach USD 53.63 billion in 2032, growing at a CAGR of 7.30% over the forecast period (2024-32).
• Based on type, the global dyslexia treatment and diagnosis market is divided into phonological dyslexia, surface dyslexia, and others. The phonological dyslexia segment is responsible for the largest market share and is anticipated to grow at a CAGR of 7.74% over the forecast period.
• Based on treatment and diagnosis, the global dyslexia treatment and diagnosis market is divided into treatment and diagnosis. The treatment segment is the highest contributor to the market share and is anticipated to grow at a CAGR of 6.80% over the forecast period.
• Based on end-user, the global dyslexia treatment and diagnosis market is segmented into specialty centers, home care, hospitals and clinics, and others. The specialty center segment owns the highest market share and is expected to grow at a CAGR of 6.63% over the forecast period.
• North America is the most significant contributor to the global dyslexia treatment and diagnosis market and is anticipated to grow at a CAGR of 6.15% during the forecast period.

Competitive Players

1. Pfizer, Inc.
2. Teva Pharmaceutical Industries Ltd.
3. Novartis AG
4. Jubilant Pharma Limited
5. GSK plc
6. Eli Lilly and Company
7. Otsuka Holdings Co., Ltd.
8. Apotex Corporation
9. Purdue Pharma
10. Rhodes Pharmaceuticals L.P.
11. Cian Healthcare Pvt. Ltd.
12. Wallace Pharmaceuticals Ltd.
13. The Himmel Group
14. Astrazeneca
15. Sun Pharmaceutical Industries Ltd.
16. Takeda Pharmaceutical Company Limited
17. Lupin

Recent Developments

Recent Developments

• January 2024 - A novel therapeutic strategy is being facilitated by Dysolve, the first artificial intelligence-powered platform for resolving dyslexia and related learning difficulties. Dyslexia is a neurological learning impairment that causes difficulties with reading, writing, and spelling for both adults and children. One in five persons suffer from the illness, which accounts for 80% to 90% of those with learning difficulties.
• May 2024 - According to Senator England, the new bill will provide Mississippi's public schools with "a Swiss Army knife of a teacher." An interest group is attempting to persuade Governor Tate Reeves (R) to veto a law that seeks to make dyslexia therapy available to more pupils. The bill's sponsor is concerned about this. SB 2681, a bill presented by state senator Jeremy England (R) this session, would permit teachers who are certified in another state to offer dyslexia rehabilitation services to pupils in Mississippi's public schools.

Segmentation

1. By Type
   1. Phonological Dyslexia
   2. Surface Dyslexia
   3. Double Deficit Dyslexia
   4. Others
2. By Drug Class
   1. Antihistamines
   2. Central Nervous Stimulant
   3. Selective Norepinephrine Reputake Inhibitors
   4. Others
3. By End-User
   1. Psychiatric Institutions
   2. Rehabilitation Centres
   3. Home Care 
   4. Others